Generic drugs cost 30x more in poor countries: report
Generic medicines can cost up to 30 times more in poor countries, according to a new study.
Amphastar enters into $59m settlement with Sandoz and Momenta
US pharmaceutical company Amphastar Pharmaceuticals is to receive $59.9 million in a settlement agreement with two of its competitors, Sandoz and Momenta Pharmaceuticals.
US officials call for review of government-owned IP management
A US congressman and senator have asked the country’s audit institution, the Government Accountability Office to review the management of government-owned IP in the health sector.
Pharma companies join forces to block list price disclosure
Pharmaceutical companies Merck & Co, Eli Lilly, and Amgen are suing the US Department of Health and Human Services over proposed rules which would force companies to disclose the list prices of drugs in TV advertisements.
English High Court upholds Sequenom patent for prenatal test
US-based gene sequencing company Sequenom was handed a win yesterday after a UK court ruled that The Doctors Laboratory and Ariosa Diagnostics, which is owned by Roche, had infringed its patent.
Pfizer to acquire Array BioPharma for $11.4bn
US biopharmaceutical company Pfizer has entered agreed to acquire Array BioPharma, a biotechnology company which develops small molecule drugs for the treatment of cancer.
FDA selects Merck, IBM, KPMG and Walmart for blockchain pilot
The US Food and Drug Administration has chosen Merck & Co, IBM, KPMG, and Walmart to form a pilot project aimed at evaluating the use of blockchain to protect pharmaceutical product integrity.
GSK unites with CRISPR pioneer Doudna
British-based pharmaceutical company GSK has entered into a five-year collaboration with the University of California to explore how gene mutations cause disease and accelerate drug discovery.
Dassault Systèmes makes $5.8bn health data deal
Software company Dassault Systèmes has targeted the life sciences sector with the $5.8 billion acquisition of Medidata Solutions, a US-firm firm focused on clinical trials.
BASF appeals to Federal Circuit in agritech dispute
BASF Plant Science, the plant biotech-focused subsidiary of BASF, has asked the US Court of Appeals for the Federal Circuit to overturn a finding that certain claims of a transgenic plant technology patent were invalid.
